Home > RNA Delivery > Adjuvant Molecules > TLR agonist small molecule

Loxoribine

  Cat. No.:  DC28230   Featured
Chemical Structure
121288-39-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 121288-39-9
Chemical Name: Loxoribine
Synonyms: Guanosine,7,8-dihydro-8-oxo-7-(2-propen-1-yl)-;7-Allyl-7 8-Dihydro-8-Oxoguanosine 95;7-ALLYL-7,8-DIHYDRO-8-OXOGUANOSINE;7-Allyl-7,8-dihydro-8-oxoguanosine (Loxoribine);7-Allyl-7,8-dihydro-8-oxoguanosine (Loxoribine);7-allyl-8-oxoguanosine;RWJ 21757;7-allyl-8-oxo-G;Loxoribine;7,8-Dihydro-8-oxo-7-allyl-guanosine;7,8-Dihydro-8-oxo-7-(2-propenyl)guanosine;Guanosine, 7,8-dihydro-8-oxo-7-(2-propenyl)-;7-Allyl-2-amino-9-(3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7,9-dihydro-1H-purine-6,8-dione;7-Allyl-7,8-dihydro-8-oxoguanosine 95%;7-ALLYL-7 8-DIHYDRO-8-OXOGUANOSINE 95;7-Allyl-8-oxoguanosine
SMILES: C=CCN1C2=C(N(C1=O)[C@H]3[C@H](O)[C@H](O)[C@H](O3)CO)NC(NC2=O)=N
Formula: C13H17N5O6
M.Wt: 339.30398
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist[1][2][3].
Target: TLR7[1]
In Vivo: Loxoribine (2 mg; s.c.or i.v.) activates murine natural killer (NK) cells in vivo[3]. Animal Model: 8-12 weeks male CBA/J mice[3] Dosage: 2 mg Administration: Subcutaneous or intravenous injection Result: activates murine natural killer (NK) cells in vivo.
In Vitro: Loxoribine induces maturation of human monocyte-derived dendritic cells DCs and stimulates their Th-1- and Th-17-polarizing capability[2]. Loxoribine (250 μM; 48 hours) stimulates maturation of MoDCs as shown by up-regulation of CD80, CD83, CD40, CD54 and CCR7[2]. loxoribine activates cells of the innate immune system selectively via the Toll-like receptor (TLR) 7/MyD88-dependent signaling pathway[1].
References: [1]. Heil F, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97. [2]. Dzopalic T, et al. Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability. Int Immunopharmacol. 2010 Nov;10(11):1428-33. [3]. Pope BL, et al. In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine). Int J Immunopharmacol. 1992 Nov;14(8):1375-82.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC66456 TLR7/8 agonist 1 TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline.
DC66322 WAY-327512 activate TLR8-dependent NF-kB signaling
DC60236 Imiquimod hydrochloride Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19.
DC31070 M1002 M1002 is a first-in-class HIF-2a agonists.
DC31025 TLR4-IN-C34 TLR4-IN-C34 is an orally active TLR4 inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis[1][2].
DC73563 E6742 E6742 (E6742) is a potent, selective, dual TLR7/8 inhibitor with binding Kd of 1.7 uM/37 nM in ITC assays, respectively, inhibits TLR7/8 agonist CL097 induced reporter activation with IC50 values of 22, 68, and 3.0 nM for hTLR7, mTLR7, and hTLR8, respecti
DC73561 E104 E014 is a potent, selective TLR7 agonist with EC50 of 69 nM in Ramos Blue reporter assays, >500-fold selective for TLR7 over TLR8.
DCC5384 Vb-201 Novel anticryptosporidial agent, acting as a toll-like receptor-2 (TLR2) antagonist
DCC4810 Smu-z1 Novel potent TLR1/2 Specific Agonist, Suppressing Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes
DC50032 CU-CPT17e CU-CPT17e shows strong NF-κB activation in TLR3, TLR8 and TLR9 HEK293 cells with EC50 values of 4.80±0.73, 13.5±0.58 and 5.66±0.17 μM, respectively. CU-CPT17e significantly improves the activity with 13.9±0.9 fold of NF-κB activation and an EC50 value of 4.8±0.7 μM. CU-CPT17e inhibits the proliferation of HeLa cancer cells by triggering apoptosis and arresting the cell cycle at the S phase. The induction of apoptosis by CU-CPT17e in HeLa cells is investigated. HeLa cells are cultured with increasing concentrations of CU-CPT17e or poly I:C or blank control (DMSO) for 24 h. Treatment with CU-CPT17e for 24 h at different concentrations (10 to 40 μM) results in an elevation of apoptotic cell population ranging from 10% to 17%, which is more effective than poly I:C at 5 μg/mL. These results suggest that the antiproliferative activity of CU-CPT17e against HeLa cells might result from its ability to directly induce apoptosis[1].
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia